Position in ACLX
as of Mar 31, 2026
· filed May 5, 2026
Position Value
$22,356,486
+$1,713,385 QoQ
Shares Held
194,709
-38.5% QoQ
Ownership
0.333%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2022
17 quarters on record
Voting authority
Sole 99%
Shared 0%
None 1%
Common Shares in ACLX Over Time
Shares Held
Position Value (USD)
Derivatives in ACLX
reported options exposure · as of Mar 31, 2026CallValue
$1,412,286
CallShares
12,300
PutValue
$1,940,458
PutShares
16,900
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026UBS Group AG holds $8,307,109,707 across 562 Biotechnology names. ACLX ranks #66 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ROIV |
Roivant Sciences Ltd.
|
22,619,472 | $626,559,372 | |
| 2 | PTGX |
Protagonist Therapeutics, Inc
|
5,177,796 | $545,739,697 | |
| 3 | ABVX |
Abivax S.A.
|
4,547,406 | $506,353,656 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
4,386,791 | $426,615,424 | |
| 5 | INSM |
INSMED Inc
|
1,737,481 | $284,112,890 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
630,618 | $281,596,158 | |
| 7 | APLS |
Apellis Pharmaceuticals, Inc.
|
6,206,681 | $249,694,775 | |
| 8 | REGN |
Regeneron Pharmaceuticals, Inc.
|
299,979 | $231,775,770 |
All Filings in ACLX
Export CSV
19 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,412,286 | 12,300 | Call | Defined | 2026-05-05 | |
| 2026-03-31 | $1,940,458 | 16,900 | Put | Defined | 2026-05-05 | |
| 2026-03-31 | $22,356,486 | 194,709 | Shares | Defined | 2026-05-05 | |
| 2025-12-31 | $20,643,101 | 316,612 | Shares | Defined | 2026-01-29 | |
| 2025-09-30 | $15,547,768 | 189,376 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $9,806,183 | 148,917 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $13,747,922 | 209,572 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $15,916,164 | 207,539 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $4,790,383 | 57,363 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $3,508,813 | 63,577 | Shares | Defined | 2024-08-14 | |
| 2024-03-31 | $7,197,103 | 103,481 | Shares | Defined | 2024-05-13 | |
| 2023-12-31 | $5,385,997 | 97,045 | Shares | Defined | 2024-02-09 | |
| 2023-09-30 | $1,773,619 | 49,432 | Shares | Defined | 2023-11-09 | |
| 2023-06-30 | $3,842,051 | 121,507 | Shares | Defined | 2023-08-11 | |
| 2023-03-31 | $30,562 | 992 | Shares | Defined | 2023-05-12 | |
| 2022-12-31 | $75,621 | 2,441 | Shares | Defined | 2023-02-08 | |
| 2022-09-30 | $3,503,926 | 186,677 | Shares | Defined | 2022-11-10 | |
| 2022-06-30 | $3,555,558 | 196,657 | Shares | Sole | 2022-08-10 | |
| 2022-03-31 | $3,172,178 | 226,261 | Shares | Sole | 2022-05-16 | |
| No filing history on record for this holder in this stock. | ||||||